DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience.

June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom (DXCM.O), opens new tab glucose sensors it bought from licensed distributors had been ‌slated for destruction, after ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

May 26 (Reuters) - Medical device maker Dexcom said on Tuesday some of its glucose sensors slated for destruction were instead stolen and sold, prompting the company to warn users not to use products ...

Michelle Tarver, director of the FDA’s Center for Devices and Radiological Health, said in the announcement that the clearance reflects the agency’s commitment to fostering innovation for pediatric ...

Every day there are new posts in a Facebook group — 89.5 thousand members strong — dedicated to Dexcom G7 issues and complaints. From inaccurate CGM readings and sensor failures to frustrating ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

Last week, the biosensor field reported innovations ranging from medical diagnostics to basic research. Of particular note are the FDA approval of Dexcom's Stelo as the first OTC CGM for ...